Multiple and Secondary Primary Cancers

Short-term mortality following the last dose of immune checkpoint inhibitors (ICIs) is an increasingly recognized real-world outcome measure, yet its clinical predictors remain poorly characterized. This multicenter retrospective study included 458 consecutive patients with advanced melanoma, non-small cell lung cance…

• BÜLENT YILDIZ

Aims: To retrospectively evaluate the demographic, epidemiological, and clinical characteristics of patients diagnosed with lung cancer. Methods: Patients diagnosed and treated for lung cancer in our medical oncology clinic were included in the study. Patient records were obtained retrospectively from the electronic d…

No abstract yet.

Progression from non–muscle-invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC) remains a major clinical challenge, particularly at the T2 stage. This study aimed to evaluate pathological stage concordance and survival outcomes between patients with primary and progressive T2 MIBC following radica…

BACKGROUND: This study aimed to describe the clinicopathological characteristics of renal cell carcinoma (RCC) in young adults (≤ 40 years) and reclassify tumour subtypes in accordance with the 2022 World Health Organization (WHO) classification, with exploratory assessment of outcome-related associations. METHODS: In…

Objective: This study evaluates the clinical and prognostic features of patients with marginal zone lymphoma (MZL) and examines the impact of key prognostic factors-LDH, β2-microglobulin, IgM levels, and IPI scoreon survival outcomes.It also compares survival among extranodal, nodal, and splenic subtypes to reveal pro…

Seventy-three-year-old man with previous diagnosis of bladder carcinoma with suspicious pulmonary nodule and rectum polypoid lesion in a follow-up 18 F fluorodeoxyglucose PET-CT examination. The histopathology results revealed lung adenocarcinoma as well as rectum adenocarcinoma and ring cell tumor of the stomach, whi…

e15006 Background: Cancer of unknown primary (CUP) is a heterogeneous metastatic entity lacking an identifiable tissue of origin, limiting evidence-based therapy. Leveraging large-scale genomic data, machine-learning approaches can stratify CUP into biologically informative subgroups. Methods: Using AACR GENIE data, w…

No abstract yet.

No abstract yet.

BACKGROUND: We aim to evaluate the co-occurrence of prostate cancer (Pca) and bladder cancer (Bca). We also aim to identify their clinicopathological characteristics and oncological outcomes in accordance with their status as either synchronous or metachronous during oncological follow-up. METHODS: Retrospective data…

No abstract yet.